{"id":"vaccine-produced-in-new-facility","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vaccines work by introducing an antigen (or instructions to produce one) that trains the adaptive immune system to recognize and mount a protective response against a specific pathogen. Without knowing the vaccine type or target pathogen, the exact mechanism—whether it uses live attenuated virus, inactivated virus, viral vector, mRNA, or protein subunit technology—cannot be determined. The new facility designation indicates a manufacturing location change rather than a mechanistic innovation.","oneSentence":"A vaccine produced in a new manufacturing facility that stimulates the immune system to prevent infectious disease, though the specific pathogen target is not specified.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:38:53.817Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT04531098","phase":"PHASE3","title":"A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2006-03-02","conditions":"Hepatitis B","enrollment":402},{"nctId":"NCT01567865","phase":"PHASE4","title":"Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-05","conditions":"Japanese Encephalitis","enrollment":818}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vaccine produced in new facility","genericName":"Vaccine produced in new facility","companyName":"PATH","companyId":"path","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}